LRI Investments LLC Has $1.17 Million Stock Position in Edwards Lifesciences Corporation $EW

LRI Investments LLC raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 1.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,971 shares of the medical research company’s stock after acquiring an additional 147 shares during the period. LRI Investments LLC’s holdings in Edwards Lifesciences were worth $1,171,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Jennison Associates LLC raised its stake in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Edwards Lifesciences by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after buying an additional 264,311 shares in the last quarter. Nuveen LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $330,881,000. Invesco Ltd. raised its stake in shares of Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after buying an additional 107,241 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Edwards Lifesciences by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after buying an additional 198,882 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 1.6%

EW stock opened at $74.02 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.00. The stock has a market capitalization of $43.46 billion, a price-to-earnings ratio of 10.65, a P/E/G ratio of 3.55 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business has a fifty day moving average price of $78.09 and a 200 day moving average price of $76.13.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company posted $0.70 earnings per share. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on EW. Evercore ISI set a $88.00 price target on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Tuesday. William Blair raised Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Wells Fargo & Company increased their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Barclays increased their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Finally, Piper Sandler increased their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.